Skinner, W L; Murray, D; Kohli, V et al. (1990) Resistance to 4-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in human myeloid leukaemia. Br J Cancer 61:51-5
|
Kantarjian, H M; Keating, M J; Walters, R S et al. (1989) Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer 63:813-7
|
Estey, E; Smith, T L; Keating, M J et al. (1989) Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 3:257-63
|
Kantarjian, H M; Walters, R S; Keating, M J et al. (1989) Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer 64:16-22
|
Keating, M J; Kantarjian, H; Smith, T L et al. (1989) Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 7:1071-80
|
Kantarjian, H M; Walters, R S; Smith, T L et al. (1988) Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood 72:1784-9
|
Keating, M J; Smith, T L; Kantarjian, H et al. (1988) Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia 2:403-12
|
Kantarjian, H M; Dixon, D; Keating, M J et al. (1988) Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61:1441-6
|
Kantarjian, H M; Walters, R S; Keating, M J et al. (1988) Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer 62:672-6
|
Walters, R S; Kantarjian, H M; Keating, M J et al. (1988) Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer 62:677-82
|
Showing the most recent 10 out of 57 publications